Nat Rev Drug Discov. 2011 Feb;10(2):79-80. doi: 10.1038/nrd3360.

An accelerated pathway for targeted cancer therapies.

McClellan M, Benner J, Schilsky R, Epstein D, Woosley R, Friend S, Sidransky D, Geoghegan C, Kessler D.

Source

Engelberg Center for Health Care Reform, Brookings Institution, Washington DC, USA.

Abstract

A well-defined pathway for the accelerated development and approval of targeted cancer therapies and companion diagnostics would reduce uncertainty, improve efficiency in development and provide an effective incentive for developers.

PMID:: 21283090; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

Antineoplastic Agents

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Advances in cancer therapeutics. [Clin Pharmacol Ther. 2009]
Advances in cancer therapeutics.
Sparreboom A, Verweij J. Clin Pharmacol Ther. 2009 Feb; 85(2):113-7.
Take-home message: are we "off target"? [Drug News Perspect. 2007]
Take-home message: are we "off target"?
Khurdayan VK. Drug News Perspect. 2007 Jun; 20(5):345-51.
Are targeted therapies really targeted? [Clin Adv Hematol Oncol. 2003]
Are targeted therapies really targeted?
Schilsky RL. Clin Adv Hematol Oncol. 2003 Dec; 1(12):722-3.
Review Development of ligand-targeted liposomes for cancer therapy. [Expert Opin Ther Targets. 2004]
Review Development of ligand-targeted liposomes for cancer therapy.
Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. Expert Opin Ther Targets. 2004 Aug; 8(4):335-53.
Review Targeted cancer therapies in the twenty-first century: lessons from imatinib. [Clin Pharmacol Ther. 2010]
Review Targeted cancer therapies in the twenty-first century: lessons from imatinib.
Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Clin Pharmacol Ther. 2010 May; 87(5):543-52. Epub 2010 Mar 17.

See reviews... See all...

Cited by 3 PubMed Central articles

Assessing the efficacy of molecularly targeted agents on cell line-based platforms by using system identification. [BMC Genomics. 2012]
Assessing the efficacy of molecularly targeted agents on cell line-based platforms by using system identification.
Li X, Qian L, Hua J, Bittner ML, Dougherty ER. BMC Genomics. 2012; 13 Suppl 6:S11. Epub 2012 Oct 26.
Clinical trials in the era of personalized oncology. [CA Cancer J Clin. 2011]
Clinical trials in the era of personalized oncology.
Maitland ML, Schilsky RL. CA Cancer J Clin. 2011 Nov-Dec; 61(6):365-81. Epub 2011 Oct 27.
Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents. [Mol Cancer Ther. 2011]
Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.
Rao TD, Rosales N, Spriggs DR. Mol Cancer Ther. 2011 Oct; 10(10):1939-48. Epub 2011 Aug 4.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

An accelerated pathway for targeted cancer therapies.
An accelerated pathway for targeted cancer therapies.
Nat Rev Drug Discov. 2011 Feb ;10(2):79-80. doi: 10.1038/nrd3360.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: